Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
2021 · European Journal of Cancer · 180 citations
https://doi.org/10.1016/j.ejca.2021.03.010
S
Sofiya Latifyan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
58
Papers
2.9K
Citations
12
h-index
14
i10-index
Sofiya Latifyan is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Cutaneous Melanoma Detection and Management. The author has an h-index of 12, co-authored 50 publications.
ORCID: 0000-0001-5117-069XPapers by this author
worksTargeting immune checkpoints in breast cancer: an update of early results
2017 · ESMO Open · 155 citations
https://doi.org/10.1136/esmoopen-2017-000255
Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series
2023 · Journal of Neurology · 17 citations
https://doi.org/10.1007/s00415-023-12134-x
Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy
2024 · Annals of Oncology · 11 citations
https://doi.org/10.1016/j.annonc.2024.12.004
Tumor-reactive clonotype dynamics underlying clinical response to TIL therapy in melanoma
2023 · bioRxiv (Cold Spring Harbor Laboratory) · 8 citations
https://doi.org/10.1101/2023.07.21.544585
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat